Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
Recruitment status was Recruiting
Hypothesis 1: Patients with psoriasis will have clinical and laboratory assessments differing from control patients.
Hypothesis 2: Patients with psoriasis will have laboratory alterations that correlate with other clinical characteristics of their psoriasis.
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis|
- Obesity risk assessment [ Time Frame: 6 months ] [ Designated as safety issue: No ]Body Mass Index; C-reactive protein (CRP)
Biospecimen Retention: Samples With DNA
|Study Start Date:||April 2010|
|Estimated Study Completion Date:||April 2011|
Children with psoriasis Age matched controls without psoriasis or other significant inflammatory disease
Age matched, without psoriasis or significant inflammatory disease
Psoriasis was initially considered an inflammatory condition primarily of the skin. However, advances in medical knowledge have allowed insight into the wide-ranging systemic effects of long-term uncontrolled inflammation, thus shifting the concept of psoriasis from an inflammatory disease restricted to the skin to a systemic process. Adults w/ psoriasis have higher rates of obesity, hypertension, diabetes, hyperlipidemia and smoking and the prevalence of each risk factor increases as the extent of psoriasis increases.1 It is uncertain if any of this relates to a behavioral reaction to having psoriasis or as a separate part of the disease process. Inflammation has a role in the pathogenesis of cardiovascular disease most noted by multiple observational studies of psoriasis patients which demonstrate an increased risk of arterial or venous events, notably myocardial infarction, cerebrovascular events, pulmonary emboli, cardiovascular death or mortality overall. Specifically, Gelfand et. al. show an increased relative risk for myocardial infarction and an increased hazard ratio for mortality in patients with severe psoriasis, but most notably, show highest risk in younger adult patients. There is a paucity of data on risks with psoriasis in the pediatric and adolescent age group.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01122095
|Contact: Lawrence F. Eichenfield, MDfirstname.lastname@example.org|
|Contact: Donna Pascual, LVNemail@example.com|
|United States, California|
|Rady Children's Hospital Dermatolgoy||Recruiting|
|San Diego, California, United States, 92123|
|Contact: Donna Pascual, LVN 858-576-1700 ext 4295 firstname.lastname@example.org|
|Contact: Ann Funk, RN, CCRC 858-576-1700 ext 4295 email@example.com|
|Sub-Investigator: Wynnis Tom, MD|
|Principal Investigator:||Lawrence F. Eichenfield, MD||University of Calfornia, San Diego|